Insulet | PODD - Sales Revenues


Insulet reported $761.7M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Abbott USD 12.59B 1.43B Jun/2026
Align Technology USD 1.04B 10M Mar/2026
AtriCure USD 141.2M 700K Mar/2026
Avanos Medical USD 182.2M 1.3M Mar/2026
Baxter International USD 2.7B 270M Mar/2026
Becton, Dickinson and Co. USD 4.7B 600M Mar/2026
Boston Scientific USD 5.2B 90M Mar/2026
Cardinal Health USD 60.9B 4.73B Mar/2026
Cooper Companies USD 1.08B 57.4M Mar/2026
Dexcom USD 1.19B 70M Mar/2026
Edwards Lifesciences USD 1.65B 80M Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Globus Medical USD 759.85M 66.55M Mar/2026
ICU Medical USD 525.77M 14.93M Mar/2026
Inogen USD 74.93M 504K Sep/2024
Insulet USD 761.7M 22.1M Mar/2026
Integra LifeSciences USD 391.9M 43M Mar/2026
J&J USD 25.31B 1.21B Jun/2026
Medtronic USD 9.8B 800M Mar/2026
Merit Medical Systems USD 381.9M 12M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Solventum Corp USD 2.01B 20M Mar/2026
Stryker USD 6B 1.2B Mar/2026
Tandem Diabetes Care USD 247.22M 43.18M Mar/2026
Teleflex USD 548.3M 20.68M Mar/2026
West Pharmaceutical Services USD 844.9M 39.9M Mar/2026
Zimmer Biomet Holdings USD 2.09B 150M Mar/2026